Using Magnetic Resonance Imaging (MRI) and applying analytical techniques —description, prediction and prescription— are key to efficiently determine whether people suffer from a neurodegenerative disease or not.
Early detection of a mild cognitive impairment or any kind of dementia is essential both for future researches in diagnosis and therapies, and healthcare management of patients who are still on stages in which treatments currently under development might presumably be more effective.
What is ADMIRE?
ADMIRE (Alzheimer’s Disease Medical Images Research Environment) is an alert system designed to support medical specialists in research, early diagnosis, prognosis and treatment planning of Alzheimer’s disease (AD).
On the basis of anonymous numerical data extracted from Magnetic Resonance Imaging (MRI), the system determines at what stage of AD a patient is, and an individual diagnosis is suggested among the following ones: Control, Amnestic Mild Cognitive Impairment (A-MCI), Multi-Domain Mild Cognitive Impairment (MD-MCI) and AD.
How does ADMIRE work?
Using DIGNA as a prerequisite, the most relevant information from MRI can be visualized in ADMIRE, obtain diagnoses suggestions on Alzheimer’s disease and predictions about the effectiveness and use of different MRI techniques.
ADMIRE uses DIGNA descriptive and predictive analytics techniques and is supported by several visualization techniques such as Social Network Analysis techniques (SNA) to offer recommendations and alerts to medical specialists, who are the ones that must evaluate and validate recommendations in the end.
Some of the advantages offered by ADMIRE are:
It warns professionals in case their diagnosis does not match the diagnosis generated by the system.
It allows doctors to monitor information of the most relevant biomarkers of patients for every stage of the disease and to carry out comparative analyses.
It shows a graph with connections between variables and their influence in every phenotype and their combinations.
ADMIRE is the result of the collaboration of a multidisciplinary team composed by IIC experts, Fundación CIEN (Research Centre for Neurological Disease), Fundación Reina Sofía, Fundación DIM (for the Development of Advanced Medical Images) and Universidad Rey Juan Carlos. This successful partnership justifies the product solidity and the results obtained.
Why invest in ADMIRE?
ADMIRE has been developed with 100% IIC technology, a fully automatic system and designed for self-learning. It permits to evaluate —with an accuracy of over 90%— the risk of every subject to belong to a group of patients according to the stage of their neurodegenerative disease.
Solutions implemented so far
ADMIRE can be used by neurologists, psychiatrists, geriatricians, neuroradiologists, neuropsychologists, biologists, etc., who work with local healthcare services, pharmaceuticals, hospitals, medical research groups, foundations and all kinds of institutions working on the study and treatment of neurodegenerative diseases and on the promotion of multicentre translational research in dementia, mainly in Mild Cognitive Impairment and Alzheimer’s Disease.
ADMIRE uses DIGNA descriptive and predictive analytics techniques.